The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how electrical systems stocks fared in Q4, starting with Thermon (NYSE:THR).
Although the S&P 500 is down 1.4% over the past six months, Alight’s stock price has fallen further to $6.01, losing shareholders 18% of their capital. This was partly due to its softer quarterly results and might have investors contemplating their next move.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at aerospace and defense stocks, starting with Cadre (NYSE:CDRE).
Shareholders of Cars.com would probably like to forget the past six months even happened. The stock dropped 31.7% and now trades at $12.09. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
In a sliding market, 8x8 has defied the odds, trading up to $2.18 per share. Its 13% gain since September 2024 has outpaced the S&P 500’s 1.4% drop. This run-up might have investors contemplating their next move.
Over the past six months, Vishay Intertechnology’s shares (currently trading at $17.15) have posted a disappointing 7.2% loss while the S&P 500 was down 1.4%. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
What a brutal six months it’s been for Regeneron. The stock has dropped 39.3% and now trades at $662.80, rattling many shareholders. This might have investors contemplating their next move.
Over the last six months, Light & Wonder shares have sunk to $104.34, producing a disappointing 7.4% loss - worse than the S&P 500’s 1.4% drop. This might have investors contemplating their next move.
What a time it’s been for VSE Corporation. In the past six months alone, the company’s stock price has increased by a massive 44%, reaching $120 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season.
